TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: self-reporting function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: step testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet-activating factor-induced platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: walking performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fold increase of HAI antibodies to A/California/07/2009
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: adequate chest compressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: bystander fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: postprandial energy expenditure (EE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accuracy of subacromial bursal injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged protection against AHR to AMP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of postdischarge nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postdischarge vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative impact on quality of living due to emetic symptoms
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total satisfying sexual activity
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Sexual desire
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Personal distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Defensin expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inflammatory marker levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean amount of activated charcoal ingested
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of MVO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LV volume and function impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC for predicting ECE status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anterior knee pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: worst pain in the past week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appropriate clinical follow-up at 1 year
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean glaucoma knowledge assessment score (GKAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Global assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean time to first analgesic request
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean pH during nocturnal period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of time with pH >4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Unified Parkinson's Disease Rating Scale motor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage agreement between clinician and patient on CD status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alteration in sealed area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of caries lesion formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: meal energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of petechial haemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of lesions associated with epithelial disruption
Endpoint domain: Adverse events/effects
Primary endpoint:  IELT (Intravaginal Ejaculatory Latency Time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTA-unassisted patency at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Construct validity of the FWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Home Blood Pressure (HBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PJI risk
Endpoint domain: Adverse events/effects
Primary endpoint: decrease in fever on days 1-3
Endpoint domain: Adverse events/effects
Primary endpoint: shorter lengths of stay in hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Conjunctival recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: sternal wound infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: cost incurred
Endpoint domain: Resource use
Primary endpoint: Number of attempts for IV catheter placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportion of successful IV catheter placements in 1 attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportion of successful IV catheter placements within 2 attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: skin severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: scar depth improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: HoNOS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Attachment Level (RAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for the appearance of bowel sounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time for the passage of first flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Feeling of hunger
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Preference for PDA administration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ease of use ratings for PDA
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Instances of relapse
Endpoint domain: Mortality/survival
Primary endpoint: Mean number of toilet visits per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vasoconstriction response to L-NMMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Vasodilator response to glyceryl trinitrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Vasodilator response to serotonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Skin sensitivity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glucose-stimulated insulin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean time to recovery of (T(1)) to 10%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to recovery of (T(1)) to 90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Train-of-four (T(4)/T(1)) ratio to 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in specified symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life improvement (exercise duration)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of life improvement (SAQ score)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: blood oxygen level dependent activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: alcohol self-administration behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in endurance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BUT (Break-Up Time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Survival rate of the implants
Endpoint domain: Mortality/survival
Primary endpoint: Formation of nonphysiological scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: SF-36 Physical Component Summary score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Dyspnoea score assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients without diuretic reuse
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Preparedness of clinicians for their shift
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Early morning order entry per 100 patient-days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in youths' psychosocial functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Interest in the relationship between diet and genetics
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: high quality oocyte rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: AMH levels in serum and follicular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: COPM performance and satisfaction scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Acquisition rate of HSV-2 infection
Endpoint domain: Mortality/survival
Primary endpoint: Duration of clinical first genital HSV-2 episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of reactivation of HSV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incision size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: DASH scores at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: RSAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptomatic left ventricular systolic dysfunction (LVSD)
Endpoint domain: Adverse events/effects
Primary endpoint: declines in left ventricular ejection fraction of ≥10% points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total annual medical charges
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Annual number of visits for specialty care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Frequency of hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: wear depth of root dentine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: swallowing ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median gastric 24‐h pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Night‐time gastric acid suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Nocturnal acid breakthrough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Lowering triglyceride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lowering total cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Elevating high density lipoprotein cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anti-birch IgE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: State anxiety reductions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative 24h FEV1 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Occurrence of any adverse effect
Endpoint domain: Adverse events/effects
Primary endpoint: Ln-resistin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of acute severe reactions to snake antivenom
Endpoint domain: Adverse events/effects
Primary endpoint: local complete response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grade 3 or 4 acute bowel complications
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of losing balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphologically left ventricular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fewer readmissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total days rehospitalized
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Lower readmission charges
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Plaque rupture within the intermediate SVG lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Investigator assessment of global response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of basic tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to administration of magnesium sulfate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Teamwork performance (global score)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: zone of keratinized tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe electrolyte abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: DeltaS(Cr)%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: cCl(Cr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number needed to treat (NNT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean increase in nonvellus hair count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients achieving new hair growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-evaluation of hair growth
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction response rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: FSFI sexual function score
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: alpha-tocopherol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: lengths of lag phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of feeding tube changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of stoma site infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Episodes of emesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of nesfatin-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Taste perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rehabilitation outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GHQ-28 score improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 1-year graft occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Resolution of signs or symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensation of gas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to first bowel sounds and flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Postoperative fentanyl requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grading of symptoms by visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life improvement rates
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adverse events (tumor hemorrhage-type events)
Endpoint domain: Adverse events/effects
Primary endpoint: Emergency department attendances with chest pain
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Proportion of chest pain attendances resulting in admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily medical admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Putamen (18)F-DOPA signal decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue antiemetic medication consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in functional status with 50% or more reduction in ODI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health Assessment Questionnaire (HAQ) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lost productivity per patient-year
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of subjects with plasma HIV‐1 RNA < or = 400 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with plasma HIV‐1 RNA < or = 50 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median CD4 cell count increase from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pressure Pain Threshold (PPT) trapezius
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic expenditure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in RLP (Visual Analog Scale points)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stable hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: success rate of endoscopic DCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: OPK levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Speech abnormalities (oromotor apraxia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevention of type I diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: successful intubation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: dental trauma score
Endpoint domain: Adverse events/effects
Primary endpoint: Declarative memory performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Visuospatial memory performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Vaginal delivery not achieved within 12 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Vaginal delivery not achieved within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Cognitive dependence
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Automatization deficit
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: relapse cases
Endpoint domain: Adverse events/effects
Primary endpoint: 90-min PG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC-PG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 90-min PI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: composite of all-cause mortality, myocardial infarction, and stroke
Endpoint domain: Mortality/survival
Primary endpoint: One and three year survival rates
Endpoint domain: Mortality/survival
Primary endpoint: relapse risk
Endpoint domain: Mortality/survival
Primary endpoint: percentage of postoperative body weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: volume of preoperative meals consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of clinical pregnancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Troponin I/T elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes